Introduction
Lipoprotein lipase (LPL)' is under significant tissue-specific regulation, with diurnal variations reflecting the differential tissue needs for plasma triglycerides. In the fed state, a high adipose LPL activity with concomitantly low muscle LPL activity leads to the preferential uptake of hydrolyzed triglycerides by adipose tissue for storage. In contrast, during the fasting state, high muscle and low adipose LPL activity diverts plasma triglycerides for use as a primary energy source. A principal factor in the nutritional regulation of LPL is insulin, and a significant correlation between plasma insulin levels and adipose tissue LPL activity has been found under a variety of physiological states (1) . However, other factors must also be important because an inverse correlation between insulin levels and muscle LPL activity is not readily perceived.
Persistent insulin deficiency, as occurs in diabetes mellitus, leads to increases in plasma triglyceride and free fatty acid levels (2) . Although the increase in free fatty acid flux to the liver in the initial states of diabetes leads to an increase in VLDL synthesis, the VLDL synthetic rates decrease with prolonged diabetes (2) . However, an even greater defect develops in the removal oftriglyceride-rich lipoproteins from plasma, which is partially but not completely, due to a decrease in LPL activity (3) . The physical state of these lipoproteins seems to be affected since triglyceride-rich lipoproteins from diabetic animals are cleared more slowly than their normal counterparts when injected into normal animals (4) . The diabetic lipemia that results from insulin deficiency can be corrected with insulin treatment (5) . In view ofthe defect in the removal oftriglyceride-rich lipoproteins, much interest has focused on the regulation of LPL in diabetes, where adipose tissue LPL activity is low and unaffected by nutritional state in the absence of insulin, but normalizes with insulin administration ( 1, 6) . However, the effect of diabetes on muscle tissue has been inconsistent. Diabetic heart and skeletal muscle LPL activities have been reported to be unchanged, increased or decreased (6) . Thus, although diabetes can serve as a useful model for elucidating the in vivo regulation of LPL by insulin, the mechanisms that regulate tissue LPL activity in diabetes have not been identified. The present studies were undertaken to elucidate the possible mechanisms for the tissue-specific regulation ofLPL in diabetes. These studies indicate that diabetes induces a significant tissue-specific response in the levels of LPL mRNA, immunoreactive protein, and activity, as well as changes in the catalytic activity of the enzyme.
Methods
Animals. Young male Sprague-Dawley rats (1.5 mo) were obtained from Simonsen Laboratories (Gilroy, CA). Diabetes was induced by a tail-vein injection of streptozocin (45 mg/kg body wt) freshly diluted in 50 mM sodium citrate, pH 4.5. Control rats were injected with sodium citrate alone. Fasting plasma glucose levels were assessed from tail vein blood three days after streptozocin administration, and rats with levels > 300 mg/dl were randomly divided into three groups: (a) Diabetic rats, which were not treated further. (b) Chronic insulintreated diabetic rats, which were injected subcutaneously with Humulin N insulin (Eli Lilly & Company, Indianapolis, IN) each evening between 5 and 7 p.m. In these animals, glucose levels were monitored by tail vein blood between 8 and 10 a.m. and the insulin dose was adjusted to maintain normal plasma glucose (3-10 U). (c) Acute insulin-treated diabetic rats, which were maintained identically to diabetic (D) rats, except that a single dose of insulin (5 U) was given the night before sacrifice. The rats were maintained on a 12-h light/ 12-h dark cycle with free access to food and water. 10 d after streptozocin injection, all rats were weighed and killed between 10 a.m. and noon. Rats were killed by decapitation, a blood sample was taken for plasma glucose (7), triglyceride (7), cholesterol (7), and free fatty acids (8) . Experimental tissues were expeditiously removed and quick-frozen in liquid nitrogen. Heart samples were washed in phosphate-buffered saline prior to freezing. Tissues were stored at -70'C until they were processed.
LPL assay. Total LPL activity was measured as previously described (9) . Briefly, tissue samples were delipidated with acetone/ether and the acetone-ether powders were extracted into 100-200 M1 of5 mM sodium barbital, pH 7.5, 20% (vol/vol) glycerol and 0.1% Triton X-100, by a 30-min incubation at 4VC with intermittent vortexing. After pelleting insoluble material at l0,O00gfor 10 min, an aliquot was taken for protein determination (10) , and 25-50 Al of the extract was assayed in triplicate for LPL activity at 370C, using a [3H]triolein emulsion substrate (final concentration 2.5 mM triolein, 2.4% BSA, 0.2 M Tris, pH 8.5, 0.1 M NaCl, 8% heated horse serum in 0.25 ml) in the absence and presence of I M NaCl (high salt). Reactions were terminated after 20-60 min with the addition of3.2 ml heptane/methanol/chloroform (180:250:230) containing 20 jg/ml oleic acid, followed by 1 ml of 0.1 M sodium borate-carbonate (pH 10.5). After vortexing, the phases were separated and a 2-ml aliquot ofthe aqueous phase was mixed with scintillation cocktail, and the amount ofradioactivity was determined in a scintillation counter (Beckman Instruments, Inc., Palo Alto, CA). LPL activity was determined by subtracting the non-LPL-dependent activity (high salt) from the total lipolytic activity. Enzyme activity is expressed in pkat/mg protein, where 1 pkat = I pmol of fatty acids released * s. LPL catalytic or specific activity was calculated by dividing LPL activity in neq/h -mg protein by LPL mass (measured in an aliquot from the same sample extract) in ng/mg protein and is expressed as neq/h * ng.
Total RNA isolation. Total cellular RNA was isolated from frozen tissue as previously described (9, 11) . All glassware and plasticware were autoclaved before use. Briefly, tissues were homogenized with a polytron (heart, kidney, brain) or with a brief sonication (fat) in the presence of 4 M guanidinium thiocyanate, 0.5% sodium N-lauroylsarcosine, 25 mM sodium citrate (pH 7.0), and 0.1 M 2-mercaptoethanol (addedjust before use). RNA was purified via a series ofethanol precipitations as described by Chirgwin et al. (12) . RNA pellets were dissolved in diethylpyrocarbonate-treated sterile water, quantitated by measuring the A260/A280 ratio, and analyzed for RNA integrity by northern analysis after agarose gel electrophoresis, as described previously ( 1). LPL mRNA was visualized by hybridization using a 39-nucleotide oligomer that was synthesized (courtesy of Dr. J. Eberwine, University of Pennsylvania) to be complementary to the region of mouse LPL mRNA encoding for amino acids 15-27. The probe was prepared by end-labeling using T4 polynucleotide kinase (13) and gives a signal comparable to that obtained using a rat LPL cDNA (9). a-Actin cDNA (a kind gift of Dr. L. Kedes, University ofSouthern California) was nick-translated according to standard protocols (14) . The specific activity of the probes was 1-7 X I08 cpm/Ag and probes were used within a day ofpreparation. Total LPL mRNA was quantitated by slot blot hybridization as previously described (9, 11 (9, 15) . Briefly, aliquots of tissue extracts in buffer containing I M NaCl, 0.1% Triton X-100, 0.1% albumin, protease inhibitors, and Tris-HCl (pH 7.4) were added to 96-well microtiter plates which had been previously coated overnight with 100 Ml of affinity-purified chicken anti-LPL antibody (number 227 1-X 5400) in 0.1 M sodium carbonate, pH 9.3. After incubation for 18 h at 4VC, the wells were washed with phosphate-buffered saline containing 0.1% BSA and 0.1% Triton X-100 and biotinylated affinity purified chicken anti-LPL antibody (number 2272-Bio-15-5400) was added and incubated for an additional 18 h at 4°C. After 
Results
Animal weights. All animals were sacrificed between 10 a.m. and noon to minimize changes in LPL activity due to diurnal variations. Rats were divided into control (C), diabetic (D), chronic insulin-treated diabetic (CI), and acute insulin-treated diabetic (Al) groups. Rats initially weighed 238±1 g, and all experimental groups gained 18-47 g (P < 0.05) during the observation period. However, the untreated diabetic animals gained significantly less weight (P < 0.03) than either the control or chronic insulin-treated diabetic animals (C 286±5 g, D 258±8 g, CI 277±7 g, Al 274±3 g at sacrifice), consistent with the hyperglycemia seen in the diabetic rats. Nevertheless, this provides evidence that these animals were continuing to gain weight.
Plasma glucose and lipid levels. Diabetes induced a fourfold increase in average serum glucose levels (Fig. 1 A; C 7.2±0.3 mM vs. D 29.0±0.7 mM; P < 0.001), which were lowered to levels below control with chronic insulin treatment (CI 3.5±0.5 mM; P < 0.001). Acute insulin treatment had a wider response range, significantly lowering glucose levels compared to diabetic rats (Al 19.9±4.6 mM; P < 0.02), but still remaining higher than control rats (P < 0.01 ). No significant differences were detected in serum cholesterol levels ( Effect of diabetes on adipose tissue LPL. Experimentally induced insulin deficiency has been reported by several investigators to lead to a dramatic decrease in LPL activity in adipose tissue that is corrected by insulin treatment (6) . To elucidate the possible mechanisms that regulate these changes in adipose LPL activity, LPL activity, immunoreactive protein and mRNA were examined in epididymal fat tissue (Fig. 2) . In diabetic rats, total LPL activity ( Fig. 2 A) When the total activity and immunoreactive mass were used to calculate the catalytic or specific activity ofLPL (Fig. 2  D) , it becomes apparent that the marked decline in LPL activity with only small changes in LPL immunoreactive protein in diabetes is explained by a reduction in the specific activity of LPL in diabetes (C: 24.7±1.9 neq/hng, D: 13.2+4.9 neq/ h * ng; P < 0.05) that is corrected by both chronic and acute insulin treatment (CI 23.9±1.4 neq/h ng, Al 30.5±4.3 neq/ h * ng). Thus, while the low level of LPL activity in epididymal fat in diabetes appears to be due, in part, to a fall in LPL mRNA and immunoreactive protein, the appearance of LPL that is enzymatically inactive seems to contribute substantially.
Effect of diabetes on the heart. Reports on the effect of diabetes on heart LPL activity have been inconsistent, with investigators reporting no change, a decrease, or an increase in activity (6) . In the present study, no significant changes in total heart LPL activity (Fig. 3 A) were seen with diabetes or insulin treatment (C 89.0±6.9 pkat/mg, D 130.7±22.1 pkat/mg, CI 85.4±9.4 pkat/mg, Al 115.1±27.0 pkat/mg; P = NS), although a trend towards higher LPL activity with diabetes was observed. LPL immunoreactive protein (Fig. 3 B) paralleled the changes in LPL activity with an increase in LPL immunoreactive protein observed in diabetic animals (C 6.2±0.6 ng/mg, D 12.7±3.0 ng/mg; P < 0.02) that was normalized by chronic and acute insulin treatments (CI 6.4±0.8 ng/mg, AI 7.5±1.3 ng/mg; P < 0.01 and P < 0.05 vs. D, respectively). In contrast, LPL mRNA and activity levels were not regulated in parallel, with LPL mRNA levels (Fig. 3 C) decreasing 46% compared to control (C 57.8±4.6 U, D 31.2±3.5 U; P < 0.01). Chronic insulin treatment normalized LPL mRNA (CI 48.6±5.8 U; P < 0.01 vs. D), but acute insulin treatment had no corrective effect (AI 41.0±2.3 U; P < 0.01 vs. C). When the total activity and immunoreactive mass were used to calculate the specific Effect ofdiabetes on other tissues. The tissues with the highest LPL mRNA and activity are fat and muscle, which together account for the majority of plasma triglyceride clearance. The function of LPL in most other tissues remains either putative or unknown. To determine whether diabetes induced specific changes in LPL regulation in tissues other than adipose and muscle, the effect of diabetes on LPL in rat kidney and brain were also monitored.
In rat kidneys (Fig. 4 A) Al 
29.8±6.4 neq/h-ng; P = NS).
It has previously been reported that LPL activity in brain is reduced by 45% after the induction of diabetes in rats and that Figure 4 . The effect of diabetes on LPL activity, mass, mRNA, and specific activity in rat kidney. LPL activity and mass were measured as described in Methods. Total RNA was prepared as described in Methods, its integrity checked by Northern analysis, and the amount ofLPL mRNA quantified by slot-blot analysis. Slots were optically scanned and LPL mRNA levels reported relative to control brain, which was arbitrarily set at I U. Results are expressed as mean±SEM. this is corrected with chronic insulin treatment ( 16) . We were unable to reliably detect significant levels of LPL activity or immunoreactive protein in the brains of adult rats from control, diabetic, or insulin treated. Brain LPL mRNA was detected, and levels were not affected by diabetes or insulin treatment (Fig. 5) .
Discussion
A large body of evidence strongly implicates insulin as the major hormone in LPL regulation. Plasma insulin concentrations show the highest correlations with adipose tissue LPL activity and administration of insulin under conditions normally associated with low adipose tissue LPL activity, leads to a pronounced increase in LPL activity ( 1, 17) . Previous studies with experimentally induced diabetes in adult male rats have demonstrated a marked decrease in both total and heparin-releas- (6) . In accordance with these reports, in the present studies diabetes led to a 75% decrease in total LPL activity that was normalized, and even increased above normal, by both chronic and acute insulin treatments. The amount ofimmunologically detectable LPL in adipose tissue of diabetic rats decreased by approximately one-third, although this change failed to reach statistical significance. Interestingly, the fall in the mass of immunologically detectable LPL with diabetes closely matched the 33% decrease in LPL mRNA levels in adipose tissue that was observed, which was statistically significant. These results suggest that a decrease in the level of LPL mRNA, presumably due to a fall in the rate of LPL transcription (although it is possible that changes in LPL mRNA processing or stability contribute), and a subsequent decline in the translation of LPL or an acceleration of the half-life of LPL lead to a reduction in the amount of LPL protein, but are responsible for only a portion ofthe fall in total LPL activity in adipose tissue during diabetes. Indeed, when the specific activity of LPL in adipose tissue was calculated (LPL activity/LPL immunoreactive mass), there was an -50% decline in the specific activity of LPL in diabetic animals. This decline in the specific or catalytic activity of adipose tissue LPL in the diabetic state could result from several possibilities: first, there could be an increase in the accumulation of LPL that has been altered during translation or co-translational processing so that it is inactive or less active; second, there could be a defect in the ability to activate a pool ofLPL that is translated and processed properly, but usually stored as an inactive or less active enzyme; or third, there could be an increase in the accumulation of LPL that has been translated and activated normally, but is inactivated by an accelerated process. Whichever the mechanism, the fall in total LPL activity in diabetes can now be explained by a combination of presumed transcriptional alterations, with associated reduction in LPL mRNA and LPL protein, and by post-translational changes that allow inactive LPL to accumulate.
While insulin treatment, both chronic and acute, returned adipose tissue LPL activity to normal, or above normal, it increased the amount of immunologically detectable LPL above control. In chronic insulin-treated rats the rise in the amount of immunologically detectable LPL was associated with a return of LPL mRNA levels to normal; however, the rise in the amount of immunologically detectable LPL with acute insulin treatment occurred with LPL mRNA levels still depressed at the levels seen in diabetics. Furthermore, both chronic and acute insulin treatment corrected the depressed specific activity of LPL. Thus, the mechanisms responsible for the return of adipose tissue LPL activity appear to be multiple and to differ between chronic and acute insulin treatment. The increase in adipose tissue LPL activity with chronic insulin treatment seems to be due to an increase in LPL mRNA, presumably secondary to an increased rate of transcription ofthe LPL gene, that, in combination with an improved efficiency of translation or prolongation of the half-life of the enzyme, results in an increased amount ofLPL protein and, finally, due to the correction of the post-translational changes in LPL. The increase in activity associated with acute insulin treatment appears to be due to an improved efficiency of translation of LPL mRNA or prolongation of the half-life of the enzyme independent of any changes in LPL mRNA levels, resulting in an increase in LPL protein, combined with a correction of the post-translational abnormalities. Based on the differences between acute and chronic insulin treatment, it would appear that insulin can rapidly modulate translational and post-translational control of LPL either directly or indirectly by altering metabolic intermediates, but long-term changes in LPL activity seem to depend at least in part on control of LPL mRNA levels.
Reports on the effects of diabetes on heart LPL activity in adult rats have remained inconclusive. In the present studies, although no statistically significant changes in heart LPL activity were observed in diabetic or insulin-treated diabetic rats, there was a trend towards an elevation of LPL activity with diabetes and a return to normal with insulin treatment. Indeed, measurement ofimmunoreactive LPL protein supported these trends with a significant increase of LPL protein with diabetes and a normalization with both chronic and acute insulin treatment. In view ofthese parallel changes in LPL activity and LPL protein, the specific activity of LPL remained constant among the experimental groups. Several previous studies reporting the effects of diabetes on heart LPL activity have found either no change (18) (19) (20) or an increase in activity (21) (22) (23) . In contrast, other investigators have reported that diabetes leads to a decrease in heart LPL activity, based on studies in perfused hearts (24) , fresh tissue homogenates (25) , or isolated cardiomyocytes (26) . This variability in the literature may be due in large part to the use of different assay systems, the measurement of total versus heparin-releasable activity, the use offresh homogenates or acetone-dried powders, the use of organ perfusion systems, or isolated cells. In addition, variabilities also exist both in the manner of diabetes induction (streptozocin, alloxan, or total pancreatectomy), the dose of streptozocin or alloxan used, the duration of the diabetic state before sacrifice, and the presence or absence of ketonuria and a catabolic condition. This last factor, a catabolic state, might be most critical to the variability in the literature. It is important to note that the diabetic animals in the present study were not catabolic and all gained weight during the duration of diabetes even in the presence of marked hyperglycemia. Finally, the majority of heart LPL activity exists in intracellular pools; since the heparin-releasable pool accounts for only 25-50% of the total activity (27) , these pools of LPL may be differentially affected in diabetes and might explain the discrepancy between the normal or increased total LPL activity and immunoreactive protein found in the present study and the observation of a reduced hydrolysis oftriglyceride-rich lipoproteins by perfused diabetic hearts (24) . Although immunoreactive LPL protein was elevated in the heart in parallel to LPL activity, diabetes induced a 46% decrease in LPL mRNA levels, which were corrected by chronic, but not acute, insulin treatment. Thus, while LPL is differentially regulated in the heart and adipose tissue during diabetes and insulin treatment, it appears that LPL activity in both heart and fat is primarily regulated via post-transcriptional mechanisms. Nonetheless, these mechanisms seem to differ since the specific activity of LPL was altered in adipose tissue, but remained unchanged in heart.
Although adipose and muscle LPL activity account for the majority of total body LPL activity, a small amount of LPL activity is also found in various other tissues. LPL has been found in the kidney (28) and the kidney has been shown to hydrolyze triglycerides in circulating lipoproteins (29) . No significant changes were seen in the activity or the amount of immunologically detectable LPL in the kidney, although trends towards an increase in both activity and protein with chronic and acute insulin treatment were seen. However, both chronic and acute insulin treatment of diabetic rats led to a small, but statistically significant, increase in LPL mRNA levels. The physiological significance ofthis difference is questionable, in that the changes seen were small, and kidney LPL activity accounts for a small portion oftotal body LPL activity. Nonetheless, the data suggest that insulin might regulate the transcription ofLPL in the kidney. In the brain, LPL is thought to provide precursors for cell membrane biosynthesis, particularly during brain development. Gavin et al. ( 16) reported a 45% decrease in brain LPL activity in young adult diabetic rats, that was corrected with chronic insulin treatment, suggesting that LPL may have other roles in the brain. In the present studies, we were unable to detect LPL activity or immunoreactive protein in the brain. The reasons for this are unclear but may be due to different tissue preparations, incubation conditions, the presence of inhibitors, interfering substances, or the sensitivity ofour assays. In this regard, we have found immunoreactive LPL protein, but not activity, in the brains ofnewborn rats that declines to undetectable levels by 1 mo of age (9) . In contrast, LPL mRNA could be detected in the brains of adult rats and neither diabetes nor insulin treatment of diabetic rats had any effect on brain LPL mRNA levels. The physiological significance of these findings is uncertain.
While a number of factors that could affect LPL expression are deranged in diabetes and corrected by insulin therapy, most studies have focused on the role ofinsulin. Studies ofthe mechanisms involved in the insulin-mediated regulation of adipose tissue LPL in vitro have not been consistent. In isolated adipocytes from epididymal fat pads of nonfasted rats, insulin has been reported to stimulate LPL activity by increasing the levels of LPL mRNA and the rate of LPL synthesis, suggesting that insulin exerts its actions transcriptionally and translationally (30) . However, in mouse 3T3-LI adipocytes, LPL activity was stimulated by insulin entirely at post-transcriptional and posttranslational levels (31). This post-translational regulation may be due to a decrease in LPL degradation and/or to an increase in the mobilization of inactive LPL species. Large amounts of LPL have been reported to be in an inactive multimeric form that can be rapidly activated (32) , although this inactive pool of LPL has been questioned (33) . Studies of fasted (low insulin) and fed (high insulin) animals have yielded similarly inconsistent results. Fasting and feeding in chickens (34) and rats (35) caused parallel changes in LPL mRNA levels and LPL activity in adipose tissue and heart, suggesting pretranslational control. However, other studies in guinea pigs (36) and rats (37) also found changes in LPL mRNA levels and the rate of LPL synthesis, but these alterations could not explain the changes in LPL activity, thus suggesting post-translational control. Indeed, Doolittle et al. (37) observed that LPL mRNA levels and the rate of LPL synthesis increased while the amount of LPL enzyme remained unchanged with fasting, and that a 50% decrease in the catalytic activity of the enzyme explained the fall in LPL activity. This change in the catalytic or specific activity ofthe enzyme is very similar to that observed in adipose tissue with diabetes in the present studies. The nature of the changes responsible for the post-translational control of the specific activity of LPL are unknown, but it is possible that alterations in glycosylation (37) , dimerization (32), or other mechanisms are involved. Interestingly, the findings in the present study that heart LPL activity paralleled changes in the amount of immunoreactive LPL protein without any changes in LPL specific activity are also similar to the results found with fasting (37) and further emphasize the differences in the mechanisms regulating LPL in fat and heart.
Thus, it appears that LPL is regulated by diabetes and insulin at multiple levels. Evidence exists for the regulation of (a) the rate of transcription or the processing or stability of LPL mRNA, (b) the efficiency of or rate of translation of LPL, (c) the half-life of the protein, or (d) the post-translational control of the active form of the enzyme. In addition to the aforementioned mechanisms, insulin can regulate the release of surfacebound LPL by activating a phosphotidylinositol-specific phospholipase C, which selectively cleaves the phosphotidylinositol residues from the glycosyl phosphotidylinositol anchor to which LPL is bound (38) . Although a number of reports have examined LPL activity in patients with diabetes, only a recent study (39) has explored the mechanisms responsible for the decrease in LPL activity seen. These investigators observed that 3 mo ofimproved glycemic control with insulin or an oral hypoglycemic agent increased LPL activity, LPL immunoreactive mass, and the rate of LPL synthesis in adipose tissue without affecting LPL mRNA levels. Although these data suggest that improved glycemic control (i.e. insulin action) regulates LPL primarily at the level of translation, analysis of the data shows that post-translational control (a doubling of LPL specific activity) also occurred. Thus, it seems that the regulation of adipose tissue LPL in patients with diabetes is complex and has parallels with the regulation in the streptozocin-induced diabetic rat. The results of the present study demonstrate that diabetes and insulin treatment have profound effects on the regulation ofLPL and highlight the tissue-specific mechanisms involved in the regulation of LPL expression. Further studies are needed to elucidate the nature ofthe multiple levels of LPL regulation.
